CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.

doi:10.1002/cam4.5512

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.

Cancer medicine - 1 Mar 2023

Yamaguchi Junya, Ohka Fumiharu, Lushun Chalise, Motomura Kazuya, Aoki Kosuke, Takeuchi Kazuhito, Nagata Yuichi, Ito Satoshi, Mizutani Nobuhiko, Ohno Masasuke, Suzaki Noriyuki, Takasu Syuntaro, Seki Yukio, Kano Takahisa, Wakabayashi Kenichi, Oyama Hirofumi, Kurahashi Shingo, Tanahashi Kuniaki, Hirano Masaki, Shimizu Hiroyuki, Kitano Yotaro, Maeda Sachi, Yamazaki Shintaro, Wakabayashi Toshihiko, Kondo Yutaka, Natsume Atsushi, Saito Ryuta

Abstract excerpt

BACKGROUND: Rituximab, high-dose methotrexate (HD-MTX), procarbazine and vincristine (R-MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R-MPV have not yet been investigated. Herein, we investigated the correlation of MYD88 L265P and CD79B Y196 mutations, which are the most frequently found molecular alterations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD79 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Central Nervous System

Share to Central Nervous System Neoplasms

Share to Lymphoma, Large B-Cell, Diffuse

Share to Methotrexate

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 36478416
DOI: 10.1002/cam4.5512
PMCID: PMC10067082

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.PMID 36478416Read ↗

MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single centre experienceSemantic proximity Read ↗

Characterization of genomic alterations in primary central nervous system lymphomas.Semantic proximity Read ↗

MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.Semantic proximity Read ↗

Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.Semantic proximity Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potentialSemantic proximity Read ↗

Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.Semantic proximity Read ↗

Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.Semantic proximity Read ↗

Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.Semantic proximity Read ↗

Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.Semantic proximity Read ↗

MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.Semantic proximity Read ↗

The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.